Rhythm

Element Science Announces First Patient Save with Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)

SAN FRANCISCO–(BUSINESS WIRE)–Element Science, an innovative health technology company pioneering a next-generation digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, today announced the first patient save from a successful defibrillation early in the enrollment of the Investigational Device Exception (IDE) Study of its Jewel Patch Wearable […]

HeartSciences Provides Corporate Update and Reports Fiscal 2022 Financial Results

MyoVista FDA De Novo Resubmission Expected in Current Fiscal Year Completed IPO in June 2022 with Approximately $6.375M of Gross Proceeds Listed on NASDAQ Capital Market under Ticker HSCS Southlake, Texas, Aug. 01, 2022 (GLOBE NEWSWIRE) — – Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW)  (“HeartSciences” or the “Company”), a […]

QT MEDICAL’S Online Order, Mail Delivery, XPRESS ECG Testing Service, to Exhibit at the World’s Largest Annual Trade Show

Enabling patients to conduct electrocardiogram (ECG) tests safely and efficiently at home using PCA 500, the only medical grade 12-lead Resting ECG approved by the FDA for patient use. LAS VEGAS, July 29, 2022 /PRNewswire/ — Demand for telehealth and home care has surged drastically during the pandemic. QT Medical Inc. (QT […]

Adagio Medical Announces Publication of Cryocure-2 Data Reporting 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Discusses Current Status of iCLAS™ Cryoablation System

LAGUNA HILLS, Calif., July 28, 2022 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the publication of the results of its Cryocure-2 ultra-low temperature cryoablation (ULTC) study in patients with AF in the Journal of American College of Cardiology […]

HeartBeam Wins CVI 2022 Innovation Summit Award

Annual Awards Program Recognizes State-of-the-Art Cardiac Technologies SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, was selected as winner of the annual Cardiovascular Innovations (CVI) 2022 Innovation Summit and Shark Tank Competition held on July […]

Acutus Medical Announces Approval of its AcQMap System and AcQMap 3D Imaging and Mapping Catheter in Japan

Approval ushers in a new era of arrhythmia management in Japan through revolutionary non-contact imaging and diagnosis technology CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced approval […]

CardiAi Inc. launches “BPAro” a Brand New FDA & Health Canada approved Clinically validated 24-hour Ambulatory Blood Pressure Monitoring System with all new features including Bluetooth, Diabetes setting & Auto Interpretation of results

CALGARY, AB, July 27, 2022 /PRNewswire/ – CardiAI Inc. is pleased to announce the Global launch & distribution of their brand new 24-hour Ambulatory Blood Pressure monitoring system. BPAro is a compact, portable, German-manufactured, self-monitoring blood pressure device that uses Bluetooth for wireless data collection, which is uploaded to a secure cloud […]

ReCor Medical and Otsuka Medical Devices Announce Primary Endpoint Met in the RADIANCE II US Pivotal Trial of the Paradise™ System for the Treatment of Hypertension

PALO ALTO, Calif.–(BUSINESS WIRE)–ReCor Medical, Inc. (“ReCor”) and Otsuka Medical Devices Co., Ltd., a fully owned subsidiary of Otsuka Holdings Co., Ltd., today announced that the RADIANCE II US FDA IDE pivotal trial evaluating the Paradise™ Ultrasound Renal Denervation (uRDN) System as a treatment for hypertension met its primary efficacy […]

InCarda Therapeutics Announces Enrollment of First Patient in Pivotal Phase 3 RESTORE-1 Trial of InRhythm™ for the Treatment of Paroxysmal Atrial Fibrillation

Single Pivotal Phase 3 Trial to Support Filing of New Drug Application Positive Phase 2 Efficacy and Safety Data for InRhythm Recently Highlighted as “Editor’s Pick” in Circulation: Arrhythmia and Electrophysiology SAN FRANCISCO, July 26, 2022 (GLOBE NEWSWIRE) — InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing inhaled therapies […]